Suppr超能文献

国际白塞病诊断标准(ICBD):27 个国家对新标准敏感性和特异性的合作研究。

The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria.

出版信息

J Eur Acad Dermatol Venereol. 2014 Mar;28(3):338-47. doi: 10.1111/jdv.12107. Epub 2013 Feb 26.

Abstract

OBJECTIVE

Behçet's disease (BD) is a chronic, relapsing, inflammatory vascular disease with no pathognomonic test. Low sensitivity of the currently applied International Study Group (ISG) clinical diagnostic criteria led to their reassessment.

METHODS

An International Team for the Revision of the International Criteria for BD (from 27 countries) submitted data from 2556 clinically diagnosed BD patients and 1163 controls with BD-mimicking diseases or presenting at least one major BD sign. These were randomly divided into training and validation sets. Logistic regression, 'leave-one-country-out' cross-validation and clinical judgement were employed to develop new International Criteria for BD (ICBD) with the training data. Existing and new criteria were tested for their performance in the validation set.

RESULTS

For the ICBD, ocular lesions, oral aphthosis and genital aphthosis are each assigned 2 points, while skin lesions, central nervous system involvement and vascular manifestations 1 point each. The pathergy test, when used, was assigned 1 point. A patient scoring ≥4 points is classified as having BD. In the training set, 93.9% sensitivity and 92.1% specificity were assessed compared with 81.2% sensitivity and 95.9% specificity for the ISG criteria. In the validation set, ICBD demonstrated an unbiased estimate of sensitivity of 94.8% (95% CI: 93.4-95.9%), considerably higher than that of the ISG criteria (85.0%). Specificity (90.5%, 95% CI: 87.9-92.8%) was lower than that of the ISG-criteria (96.0%), yet still reasonably high. For countries with at least 90%-of-cases and controls having a pathergy test, adding 1 point for pathergy test increased the estimate of sensitivity from 95.5% to 98.5%, while barely reducing specificity from 92.1% to 91.6%.

CONCLUSION

The new proposed criteria derived from multinational data exhibits much improved sensitivity over the ISG criteria while maintaining reasonable specificity. It is proposed that the ICBD criteria to be adopted both as a guide for diagnosis and classification of BD.

摘要

目的

贝赫切特病(BD)是一种慢性、复发性、炎症性血管疾病,没有特定的诊断测试。目前应用的国际研究组(ISG)临床诊断标准的敏感性较低,因此需要对其进行重新评估。

方法

一个修订国际贝赫切特病标准的国际团队(来自 27 个国家)提交了 2556 例临床诊断为 BD 患者和 1163 例具有 BD 样疾病或至少有一个主要 BD 体征的对照者的数据。这些数据被随机分为训练集和验证集。使用逻辑回归、“留一国法”交叉验证和临床判断,根据训练数据制定新的国际贝赫切特病标准(ICBD)。在验证集中测试现有的和新的标准的性能。

结果

对于 ICBD,眼部病变、口腔阿弗他溃疡和生殖器阿弗他溃疡各记 2 分,而皮肤病变、中枢神经系统受累和血管表现各记 1 分。当使用帕特试验时,记 1 分。评分≥4 分的患者被归类为患有 BD。在训练集中,与 ISG 标准的 81.2%敏感性和 95.9%特异性相比,评估的敏感性为 93.9%,特异性为 92.1%。在验证集中,ICBD 显示出无偏估计的敏感性为 94.8%(95%CI:93.4-95.9%),明显高于 ISG 标准(85.0%)。特异性(90.5%,95%CI:87.9-92.8%)低于 ISG 标准(96.0%),但仍然相当高。对于至少有 90%的病例和对照者进行帕特试验的国家,增加帕特试验 1 分可将敏感性估计值从 95.5%提高到 98.5%,而特异性几乎从 92.1%降低到 91.6%。

结论

从多国数据中得出的新建议标准在保持合理特异性的同时,显著提高了 ISG 标准的敏感性。建议采用 ICBD 标准作为 BD 的诊断和分类指南。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验